Novel Small-Molecule Drug Candidate for Oncology

OCR Number: 
OCR 1642
  • GFB-204 is a novel compound that binds PDGF and VEGF and prevents binding to their respective receptors, and subsequently suppresses downstream signaling pathways.
  • GFB-204 is selective for PDGF and VEGF, and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt, and STAT3.
  • As shown in the figure, GFB-204 causes a marked decrease in tumor volume in a mouse xenograft model.
  • Inhibition of VEGF and PDGF receptor binding with GFB-204 results in potent inhibition of angiogenesis and tumorigenesis.
  • IND-enabling studies have been initiated for GFB-204 for AMD and cancer.
Sun, J., Wang, D. A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., … & Sebti, S. M. (2005). Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene, 24(29), 4701-4709.[PubMed]
Licensing Contact: